Ascendis Pharma is a global biopharmaceutical company headquartered in Copenhagen, Denmark, specializing in the development of innovative therapies using its proprietary TransCon technology platform. ... Ascendis Pharma is a global biopharmaceutical company headquartered in Copenhagen, Denmark, specializing in the development of innovative therapies using its proprietary TransCon technology platform. The company focuses on addressing unmet medical needs across endocrinology, rare diseases, and oncology. Its pipeline includes TransCon hGH for growth hormone deficiency, TransCon CNP for achondroplasia, and TransCon PTH for hypoparathyroidism, along with oncology candidates in development. Ascendis conducts clinical trials across the United States, Europe, and multinational markets, with strategic partnerships extending development efforts to Asia through entities like VISEN Pharmaceuticals in Greater China and collaborations in Japan. The company operates research facilities in Germany and offices throughout Europe and the United States, maintaining a commitment to improving treatment safety, efficacy, tolerability, and patient convenience through its innovative drug development approach.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Ascendis Pharma is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Ascendis Pharma is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Ascendis Pharma's data?

Start your 30-day free trial to request a data review for Ascendis Pharma.

Start Free Trial

Legal Center Contact Us

Ascendis Pharma A/S

Ascendis Pharma is not subject to EU Taxonomy reporting

Account Restricted